Post-earnings recap
Reported
Tue, Aug 7, 2018
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
50%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
This earnings report shows CRISPR Therapeutics is still in a development phase, with significant losses reported. Despite missing on EPS, the stock saw a slight increase of 0.43%, likely due to positive sentiment around their ongoing research efforts. Investors may be encouraged by management's focus on innovation and long-term goals.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.82 | N/A | N/A |
| Revenue | N/A | N/A | N/A |
Management expressed confidence in their research pipeline and ongoing projects. They are focused on long-term growth and innovation.
Management highlighted ongoing advancements in their gene-editing technology.
They emphasized a commitment to innovation despite current financial losses.